A Phase 1 interventional study of CSL312 in Healthy Participants, sponsored by CSL Behring. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-06.
Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, parallel-group, phase 1, single center study to assess the relative bioavailability of CSL312 administered subcutaneously via a prefilled syringe assembled to an autoinjector compared to a prefilled syringe assembled to a needle safety device in healthy, adult subjects.
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
First submitted after CSL Behring became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CSL312 administered subcutaneously (SC) in the abdomen via a prefilled syringe assembled to an autoinjector (AI)
Drug: CSL312
CSL312 administered SC in the thigh via a prefilled syringe assembled to an AI
Drug: CSL312
CSL312 administered SC in the upper arm via a prefilled syringe assembled to an AI
Drug: CSL312
CSL312 administered SC in the abdomen via a prefilled syringe assembled to a needle safety device (NSD)
Drug: CSL312
CSL312 administered SC in the thigh via a prefilled syringe assembled to a NSD
Drug: CSL312
CSL312 administered SC in the upper arm via a prefilled syringe assembled to a NSD
Drug: CSL312
Factor XIIa antagonist monoclonal antibody for subcutaneous use
Also known as: Gardacimab
Maximum plasma concentration (Cmax) of CSL312
Time frame: Up to 85 days post-dose
Area under the concentration-time curve (AUC) from time 0 extrapolated to infinite time (AUC0-inf) of CSL312
Time frame: Up to 85 days post-dose
Number and percentage of subjects experiencing adverse events (AEs)
Time frame: Up to 85 days post-dose
Number and percentage of subjects experiencing serious adverse events (SAEs)
Time frame: Up to 85 days post-dose
Number and percentage of subjects experiencing adverse events of special interest (AESIs)
Time frame: Up to 85 days post-dose
Number and percentage of subjects developing Anti-CSL312 antibodies
Time frame: Up to 85 days post-dose
Number and percentage of subjects with clinically significant laboratory abnormalities that are reported as AEs
Time frame: Up to 85 days post-dose
Number and percentage of subjects with injection site reactions by severity
Time frame: Up to 48 hours post-injection
Time to maximum plasma concentration (Tmax) of CSL312
Time frame: Up to 85 days post-dose
AUC from time 0 to the last measurable concentration (AUC0-last) of CSL312
Time frame: Up to 85 days post-dose
Half-life (t1/2) of CSL312
Time frame: Up to 85 days post-dose
Apparent clearance (CL/F) of CSL312
Time frame: Up to 85 days post-dose
Apparent volume of distribution (Vz/F) of CSL312
Time frame: Up to 85 days post-dose
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Sep 2022, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garadacimab